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Abstract
Dopamine (DA) neurons of the midbrain are at risk to become affected by mitochondrial
damage over time and mitochondrial defects have been frequently reported in Parkinson’s
disease (PD) patients. However, the causal contribution of adult-onset mitochondrial dys-
function to PD remains uncertain. Here, we developed a mouse model lacking Mitofusin 2
(MFN2), a key regulator of mitochondrial network homeostasis, in adult midbrain DA neu-
rons. The knockout mice develop severe and progressive DA neuron-specific mitochondrial
dysfunction resulting in neurodegeneration and parkinsonism. To gain further insights into
pathophysiological events, we performed transcriptomic analyses of isolated DA neurons
and found that mitochondrial dysfunction triggers an early onset immune response, which
precedes mitochondrial swelling, mtDNA depletion, respiratory chain deficiency and cell
death. Our experiments show that the immune response is an early pathological event when
mitochondrial dysfunction is induced in adult midbrain DA neurons and that neuronal death
may be promoted non-cell autonomously by the cross-talk and activation of surrounding
glial cells.
Author summary
Parkinson’s disease (PD) is a common neurodegenerative disorder characterized by pro-
gressive loss of dopamine (DA)-producing neurons and strongly compromised motor
performance. Multiple observations suggest that DA neurons are particularly prone to
acquire mitochondrial damage in adult life. This acquired mitochondrial dysfunction
likely impairs DA neuron function and contributes to cell death. To study the conse-
quences of adult-onset mitochondrial dysfunction in DA neurons, we generated a
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conditional activatable knockout mouse model lacking Mitofusin 2, a key regulator of
mitochondrial homeostasis. This animal model allows the induction of mitochondrial
dysfunction selectively in adult DA neurons and leads to motor defects and the typical
pattern of neurodegeneration seen in PD. By studying gene expression in isolated DA
neurons at early disease stages and by using in situ approaches on brain sections, we
report an early onset of an inflammatory response. Inflammation is present already when
the mutant DA neurons display the first signs of mitochondrial fragmentation and pre-
cedes the onset of respiratory chain dysfunction and neurodegeneration. The inflamma-
tory response in DA neurons and activation of surrounding glia thus likely exacerbates or
drives the neurodegenerative process in this animal model of adult-onset PD.
Introduction
Most neuronal cells have a life span similar to that of the whole organism and are rarely or
never replaced [1]. As a consequence, neurons are prone to accumulate defects which affect
their function and plasticity, and even compromise their long-term survival. The cortical sur-
face of the cerebellum and certain brain nuclei, e.g. Substantia nigra pars compacta (SNpc), are
particularly vulnerable to acquired damage [2,3], whereas other regions, e.g. hippocampus,
putamen, and hypothalamus almost completely preserve their neuronal integrity during adult
life [4]. The loss of dopamine (DA) neurons in SNpc occurs at an estimated rate of ~5–10% per
decade [5,6]. Notably, a massive degeneration of this neuronal population accounts for the
motor symptoms found in Parkinson’s disease (PD) patients. The selective vulnerability of DA
neurons seems to be caused by their intrinsic biochemical and physiological properties. DA
neurons in SNpc have rhythmic electrical (pacemaker) activity and experience increased oxida-
tive stress, presumably due to the high dopamine synthesis rate [7]. The SN is also highly
enriched in microglia cells [8], which, if activated, may generate a potentially detrimental pro-
inflammatory environment. In addition, DA neurons are thought to be particularly sensitive
to mitochondrial damage, which is mainly acquired during the lifespan of the neuron rather
than inherited. In fact, somatic deletions in the mitochondrial DNA (mtDNA) accumulate in
DA neurons in SN of aged humans [9] and PD patients [10,11] and lead to a mosaic pattern of
respiratory chain deficiency.
Over the last decades, the role of mitochondrial dysfunction in the pathophysiology of PD
has been much debated (reviewed in [12]). Although mitochondrial impairment is heavily
implicated in both idiopathic and familial forms of PD, the precise contribution of these
organelles to neurodegeneration remains unclear. There is experimental evidence that mito-
chondria are required to maintain specific cellular functions in DA neurons, such as antero-
grade axonal transport [13] and DA release by nerve terminals in the striatum [14]. In fact,
mouse models with deletions [15] or depletion of mtDNA [16] selectively in midbrain DA
neurons mirror the motor phenotypes and the typical neurodegeneration present in PD
patients. One weakness with these sets of experiments is that the mitochondrial defects are
induced in neurons already during the embryonic stage, which argue that the observed Parkin-
son-like phenotypes can be the result of both neurodevelopmental and neurodegenerative pro-
cesses. To study the effects of adult-onset mitochondrial damage in PD, we disrupted the
Mitofusin 2 (Mfn2) gene in midbrain DA neurons of adult mice. The Mfn2 gene encodes a key
component of mitochondrial fusion machinery and is therefore a major player in several mito-
chondrial pathways, e.g. trafficking, turnover, contacts with other organelles and organelle
homeostasis (reviewed in [17,18]). In mice, the tissue-specific ablation of Mfn2 in different
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neuronal circuits causes abnormalities in mitochondrial morphology and severe neurological
defects [19,20]. Here, we identify a detailed timeline of molecular events driving the severe and
progressive parkinsonism in mice with disruption of Mfn2 in the adult nigrostriatal DA sys-
tem. By using transcriptomic analyses of isolated adult midbrain DA neurons, we show that
loss of mitochondrial homeostasis triggers an early-onset immune response, that precedes DA
neuron death and therefore likely drives or exacerbates the degenerative process.
Results and discussion
Mice with adult-onset degeneration of midbrain DA neurons
To generate mice with mitochondrial dysfunction in adult DA neurons, we performed crosses
to obtain iMfn2DA mice that are homozygous for a loxP-flanked Mfn2 allele and heterozygous
for an allele expressing tamoxifen-inducible Cre-recombinase [21] under control of the DA
transporter (DAT, Slc6a3) promoter (genotype: Mfn2 loxP/loxP; +/Dat-creERT2). To activate
Cre-mediated recombination, iMfn2DA mice were injected intraperitoneally with tamoxifen
for five consecutive days at the age of 5–7 weeks (S1A Fig). The resulting mice showed a very
profound decrease in MFN2, both at transcript and protein levels, at 3 weeks after tamoxifen
injection (S1B and S1C Fig). As consequence, mice manifested a drastic reduction of life span
with maximal longevity of 12 weeks after injection (S1D Fig) and a significant decline in body
weight at 10 weeks after injection (S1E Fig). When tested in an open-field setup, tamoxifen-
injected iMfn2DA mice manifested decrease of horizontal activity, vertical activity (rearing)
and total locomotion distance at 9 weeks after tamoxifen injection (Fig 1A), whereas motor
abilities were unchanged at 3 and 6 weeks (Fig 1A). The decreased locomotion had a distinct
neuroanatomical basis as histology of brains from tamoxifen-injected iMfn2DA mice showed
degeneration of the midbrain nigrostriatal DA system (Fig 1B and 1C). Quantification of tyro-
sine hydroxylase (TH) expression identified ~50% reduction in positive nerve cell bodies in
SN (Fig 1B) and ~80% reduction in the striatal DA innervation (Fig 1C) in iMfn2DA mice ana-
lyzed at 9 weeks after tamoxifen injection. There were no significant differences between
knockouts and controls at earlier time points (Fig 1B and 1C). The profound degeneration of
the midbrain DA system in tamoxifen-treated iMfn2DA mice was further substantiated by
measurements of levels of DA and its metabolite homovanillic acid (HVA) in striatal homoge-
nates by using ultraperformance liquid chromatography-tandem mass spectrometry
(UPLC-MS/MS). The DA levels were slightly increased at 3 weeks after tamoxifen injection,
while there was a significant DA depletion at 6 weeks which became more profound at 9 weeks
(Fig 1D). The levels of HVA were significantly affected only at the late-disease stage (Fig 1D),
whereas the levels of serotonin (5-hydroxytryptamine, 5-HT) in the striatum were unchanged
over time (S1F Fig). In summary, these findings show that tamoxifen-injected iMfn2DA mice
exhibit a severe parkinsonism in adulthood caused by degeneration of the midbrain DA
system.
Mitochondrial dysfunction in adult midbrain DA neurons
To assess mitochondrial morphology in the degenerating midbrain DA neurons, we intro-
duced an allele that induces expression of mitochondrially targeted YFP (mito-YFP) after Cre-
recombinase excision of a STOP-sequence [13]. Fluorescently labelled mitochondria in TH-
expressing neurons in the midbrain (S2A Fig) showed a gradually compromised integrity of
the mitochondrial network in tamoxifen-injected iMfn2DA mice (Fig 2A). In the perinuclear
region of the soma, mitochondria became highly fragmented already 2–3 weeks after tamoxi-
fen injection and progressively more rounded and swollen after 6–9 weeks (Figs 2A and S2B),
as demonstrated by decreased mitochondrial aspect ratio and increased mitochondrial
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Fig 1. Tamoxifen-injected iMfn2DA mice show impaired locomotion and DA neurodegeneration. Control and iMfn2DA mice were
analyzed at 3, 6 and 9 weeks after tamoxifen or vehicle injection. (A) Spontaneous motor activity (horizontal activity, vertical activity and total
distance) was measured in open field. ���p< 0.001, n>14. (B-C) Representative images of TH-like immunoreactivity in section from midbrain
(Scale bars: 100 μm) and striatum (Scale bars: 200 μm), right panels. Quantification of TH-positive DA neurons in the midbrain and TH-
immunoreactive nerve terminals in the striatum, left panels. ���p< 0.001 n = 3. (D) Analysis of DA and HVA levels in the striatum. Data are
shown as mean ± SD. ���p<0.001 n�5.
https://doi.org/10.1371/journal.pgen.1009822.g001
PLOS GENETICS Mitochondrial dysfunction and immune response in Parkinson’s disease
PLOS Genetics | https://doi.org/10.1371/journal.pgen.1009822 September 27, 2021 4 / 19
Fig 2. Loss of Mfn2 in adult DA neurons affects mitochondrial morphology and cristae structure. Analyses were performed 3, 6, and 9 weeks after tamoxifen
injection in control and iMfn2DA mice. (A) Representative confocal microscopy images of YFP-labelled mitochondria (green) in TH immunoreactive neurons
(red) (Scale bars: 10 μm). (B) Quantification of aspect ratio and mitochondrial circularity from confocal images in TH+ DA neurons. AR data are shown as
mean ± SD and circularity data as median of individual mitochondria. ���p< 0.00, n = 3 for each genotype. (C) Representative electron microscopy images of
mitochondrial cristae structure (Scale bars: 1 μm).
https://doi.org/10.1371/journal.pgen.1009822.g002
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circularity (Fig 2B). Electron microscopy (EM) analysis of single organelles confirmed the ini-
tial mitochondrial fragmentation and the consequent enlargement (S2C–S2E Fig), and also
revealed structural abnormalities in mitochondrial cristae structure at 6 and 9 weeks after
injection (Fig 2C). At 6 weeks, a disruption of the outer mitochondrial membrane (OMM) was
detected in single mitochondrial profiles, and at 9 weeks, about 10% of the mitochondria in
the perinuclear region displayed ruptured OMM (S2F Fig), likely due to the alterations of
mitochondrial network and the consequent osmotic swelling of the mitochondrial matrix.
The analysis of the mitochondrial distal pool in TH positive nerve terminals identified a
dramatic decrease (~95%) in the amount of mito-YFP labelled mitochondria already at 3 and 6
weeks after injection (Fig 3A and 3B). At 9 weeks, the severe depletion of striatal mitochondria
corresponded to a massive reduction in TH immunoreactive DA fibers in iMfn2DA mice (Figs
1C and 3A). Notably, the few mitochondria found in axonal terminals (~5%) preserved their
morphology and cristae organization even at 6 and 9 weeks after injection (S2G Fig). These data
therefore confirm that the fragmented mitochondria fail to be transported in the DA axons, as
we and others have previously reported [20,22], suggesting that the maintenance of the mito-
chondrial integrity is a requirement for axonal mitochondrial transport. Furthermore, our
results indicate that in tamoxifen-injected iMfn2DA mice the degeneration of the nigrostriatal
system occurs in a retrograde fashion, i.e. from the terminal towards the cell body.
To assess oxidative phosphorylation (OXPHOS) function, we analyzed the activities of cyto-
chrome c oxidase (COX) and succinate dehydrogenase (SDH) by a combined enzyme histo-
chemical staining of midbrain tissues. At 3 weeks after tamoxifen injection, all midbrain DA
neurons of iMfn2DA mice appeared brown consistent with preserved COX activity. In contrast,
at 6 and 9 weeks after injection, a substantial proportion of midbrain cells appeared blue, con-
sistent with a profound decline in COX activity (Fig 3C).
Taken together, these findings show that tamoxifen-injected iMfn2DA mice develop a severe
adult-onset mitochondrial dysfunction in midbrain DA neurons, manifested as a progressive
fragmentation of the mitochondrial network, swelling of individual mitochondria, abnormal
mitochondrial ultrastructure and deficient respiratory chain function.
Impaired mitochondrial homeostasis causes mtDNA depletion and an
early immune response
To study pathophysiological events, we performed analysis of isolated adult DA neurons from
tamoxifen-induced iMfn2DA and control mice. We used a protocol for isolation and enrich-
ment of midbrain DA neurons from mito-YFP mouse brains based on enzymatic tissue disso-
ciation and FACS-sorting (Fig 4A). The expression of mito-YFP in isolated cells was
independently validated by confocal microscopy (S3A Fig). We collected mito-YFP positive
and mito-YFP negative cells from control and knockout mice and prepared libraries for RNA-
seq analysis using the Smart-seq2 protocol [23] (Fig 4A). Sequences were mapped to a total of
39468 genes of which 23217 protein-coding genes were used for the downstream analyses.
Hierarchical clustering analysis was performed using the most variably expressed genes and
two distinct groups were distinguished corresponding to the genotypes (Fig 4B). Well-vali-
dated DA neuronal markers (e.g. Th, Ddc and Slc6a3) and transcription factors (e.g. Nr4a2,
En1) were found abundantly expressed in mito-YFP positive cells from controls and knock-
outs and were almost undetectable in mito-YFP negative populations (Fig 4C). After confirm-
ing that the mito-YFP positive samples were highly enriched with DA neurons, FACS-sorted
cells were used to measure mtDNA levels by qPCR. Notably, at 3 weeks after tamoxifen injec-
tion, the mtDNA copy number was unaffected (Fig 4D), although the mitochondrial network
was highly fragmented (Fig 2A). In contrast, mtDNA levels were decreased to 30–40% at 6
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weeks and to 18% at 9 weeks in DA neurons isolated from tamoxifen-injected iMfn2DA mice
when compared with controls (Fig 4D). We therefore conclude that perturbations of the mito-
chondrial network precede mtDNA depletion, arguing that the loss of mitochondrial homeo-
stasis is the main cause of the observed defect. These findings are consistent with a previous
report from us showing that cardiomyocytes lacking mitochondrial fusion develop a reduction
in mtDNA copy number due to an imbalanced stoichiometry of the mtDNA replisome protein
components [24].
To gain further insights into the molecular mechanisms that precede and contribute to loss
of DA neurons, we compared the transcriptome profiles of FACS-sorted iMfn2DA and control
Fig 3. Tamoxifen-injected iMfn2DA mice exhibit impaired axonal mitochondrial transport and OXPHOS deficiency. (A) MitoYFP-labelled mitochondria in TH
+ nerve terminals of the striatum at 3, 6 and 9 weeks after tamoxifen injection (Scale bars: 10 μm). (B) Quantificantion of mitoYFP-labelled mitochondria total intensity
in the striatum of control and tamoxifen-injected iMfn2DA mice at 3, 6 and 9 weeks after tamoxifen injection. Data are shown as mean ± SD. �p< 0.05, ���p< 0.001,
n = 3 for genotype. (C) Cytochrome c oxidase and succinate dehydrogenase (COX/SDH) double-labelling enzyme histochemistry of the midbrain (Scale bars: 100 μm).
https://doi.org/10.1371/journal.pgen.1009822.g003
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Fig 4. Immune response and mtDNA depletion in tamoxifen-injected iMfn2DA mouse brains. (A) Experimental workflow: vibratome
sections were enzymatically digested and mechanically triturated resulting in a single cell suspension; the bulk of mitoYFP positive (mitoYFP
+) cells and mitoYFP negative (mitoYFP-) cells were collected by FACS; samples were used for either mtDNA quantification or for RNA
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DA neurons at 3 weeks after tamoxifen injection. By using DESeq2, 439 genes were found dif-
ferentially expressed at adjusted p value (padj) of<0.05 (listed in S1 Table). Gene ontology
and pathway enrichment analyses were performed to identify functional categories of these
genes. Unexpectedly, at this early-disease stage, when OXPHOS function, mtDNA levels and
DA neuronal survival were unaffected, the molecular pathways related to immune response
and inflammation were the most dysregulated biological processes in tamoxifen-injected
iMfn2DA mice (Fig 4E). The vast majority of significantly upregulated genes belonged to
immune system processes (Fig 5A), whose activation was mediated by the NF-KB pathway
(Fig 5B). Furthermore, the expression levels of pro-inflammatory cytokines, such as tumor
necrosis factor α (Tnf-α) and interleukin-1 β (IL-1β) were dramatically increased in tamoxi-
fen-injected iMfn2DA mice (Fig 5C). Control mice injected with tamoxifen showed no activa-
tion of the immune response (Fig 5B and 5C).
Adult-onset mitochondrial dysfunction in DA neurons triggers the
activation of surrounding glial cells
To further investigate the immune response observed in tamoxifen-injected iMfn2DA mice, we
analyzed the glial cells, microglia and astrocytes, surrounding DA neurons by confocal micros-
copy. At 3 weeks after tamoxifen injection, the immunoreactivities of IBA1 and CD45, mark-
ers of activated microglia, were moderately increased (~1.6 fold) in midbrain sections of
iMfn2DA mice (Figs 5D, 5F, S3B and S3C). Consistently, the transcript levels of different mark-
ers of reactive microglial cells, including Aif1 (Iba1), Tmem119, Ptprc (Cd45), and Itgam
(Cd11b), were significantly upregulated in iMfn2DA mice (S3D Fig). Likewise, the levels of the
glial fibrillary acidic protein (GFAP) were ~1.5 fold higher in the astrocytes residing in the
midbrain and surrounding the DA neurons. (Fig 5E and 5F). Between 6 and 9 weeks after
tamoxifen injection there was only a mild upregulation of IBA1 and CD45 (~1.8–2 fold),
whereas GFAP signal markedly accumulated over time (up to ~4 fold) (Figs 5D–5F, S3B and
S3C) suggesting that at 9 weeks after injection astrocytes were strongly activated, which closely
resembled the reactive astrogliosis observed in the late stages of neurodegenerative diseases
[25].
Finally, to identify genes potentially involved in the signaling between neurons, microglia,
and astrocytes, we interrogated the transcriptomic data. Importantly, DA neurons lacking
Mfn2 showed a significant downregulation of Anxa1 (Fig 5F) encoding the anti-inflammatory
mediator Annexin A1 (ANXA1) [26], which is normally highly expressed in DA neurons [27].
The reduction in Anxa1 gene expression in tamoxifen-injected iMfn2DA mice can potentially
explain the upregulation of pro-inflammatory markers. In support of this hypothesis, it has
been previously shown that Anxa1 overexpression in neuronal cells treated with the complex I
inhibitor methyl-4-phenylpyridinium (MPP+) can suppress pro-inflammatory responses [28].
Furthermore, the expression of both Tmem173 (STING) and Nlrp3 inflammasome genes were
significantly increased in tamoxifen-treated iMfn2DA mice (Fig 5F). Along the same lines, acti-
vation of the NLRP3 or STING pathways [29], triggered by danger-associated molecular pat-
terns (DAMPs) originating from mitochondria [30], causes a detrimental immune response in
library preparation followed by RNAseq. (B) Hierarchical clustering analysis of RNAseq data from DA neurons isolated from n = 5 iMfn2DA
and n = 6 control mice. (C) Heatmap showing that RNA levels (Reads Per Kilobase Million, RPKM) of genes encoding DA neuron markers
(Th, Ddc, Scl6a3, and Aldh1a1) and transcription factors (Nr4a2, En1, Pitx3, Foxa1 and Foxa2) are highly enriched in mitoYFP+ samples.
Data are shown as mean of the RPKM in control (n = 6), iMfn2DA (n = 5), and mitoYFP- (n = 3) mice. (D) Relative mtDNA levels (ND1/18S
rRNA and ND6/18S rRNA) measured in FACS-sorted DA neurons. �p< 0.05, ��p<0.01, n = 4. Data are shown as mean ± SD. (E) Gene
ontology (GO) analysis showing the most dysregulated biological processes in FACS-sorted DA neurons isolated from iMfn2DA mice at 3
weeks after tamoxifen injection.
https://doi.org/10.1371/journal.pgen.1009822.g004
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Fig 5. Activation of glial cells surrounding DA neurons in in tamoxifen-injected iMfn2DA mice. (A) Volcano plot displaying differential gene
expression in iMfn2DA FACS-sorted DA neurons: the 439 differentially expressed genes are represented in black and blue. The genes involved in the
immune response are represented in blue. (B) Heatmap showing the gene expression of NF-kB signaling pathway in DA neurons isolated from
iMfn2DA and control mice. (C) RNA expression levels (RPKM) of the inflammation markers Tnf-α and IL1β in mitoYFP+ cells from iMfn2DA and
control mice. Data are shown as mean ± SD. (D-E). Representative confocal microscopy image of control and iMfn2DA mouse brains at 3, 6, and 9
weeks after injection. DA neurons were labelled with an antibody against TH (red) and the brain sections were additionally labelled with antibody
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mice lacking mitochondrial transcription factor TFAM in DA neurons [31] and in Parkin and
Pink1 knockout mice after exhaustive exercise [32].
To summarize, we report here that adult-onset mitochondrial dysfunction in DA neurons
leads to degeneration of these neurons, DA depletion in the striatum and reduction of volun-
tary movement. Mice lacking Mfn2 in the mature nigrostriatal system represent a novel model
that well recapitulates major pathological features of human PD. Our results provide compel-
ling evidence that mitochondrial integrity, preserved through an intact mitochondrial fusion
machinery, is not only required during embryonic development but it is also essential for the
maintenance of the adult DA neuron population. To dissect the timeline of the molecular
events leading to neurodegeneration, we exploited bulk RNA-seq of isolated midbrain DA
neurons at an early-disease stage. Our protocol resulted in a very substantial enrichment of
midbrain DA neurons in both controls and knockouts (Fig 4C), although a minor contamina-
tion of other cell types, e.g. neighboring glial cells, was likely present in our samples (S3E Fig).
Microglial markers were indeed significantly increased in the mitoYFP positive cells isolated
from tamoxifen-injected iMfn2DA mice (S3E Fig), as these genes become highly expressed
upon glial activation. It is therefore possible that the changes in transcriptomic profile of
iMfn2DA samples were partially affected by a concomitant response in glial cells surrounding
DA neurons. Nevertheless, the conclusions of this study do not change as, in fact, our results
highlight that the adult-onset loss of mitochondrial homeostasis triggers an early immune
response that largely precedes DA neuron death and likely promotes or exacerbates the degen-
erative process. Interestingly, recent studies report that Mfn2 ablation in the adult mouse hip-
pocampus and neocortex causes neuronal cell death through neuroinflammation [33,34]. The
progression of these molecular defects resembles the order of pathological events that we have
observed in the Substantia nigra in the absence of Mfn2 suggesting that inflammation may be
a common early event in degeneration of different neuronal types, e.g. pyramidal, cortical and
DA neurons.
Numerous studies have shown that neuroinflammation is a major player in PD and may
contribute to the degeneration of the nigrostriatal DA pathway, promoting disease progression
[35]. Post-mortem examinations have revealed large numbers of reactive microglial cells [36]
and high levels of pro-inflammatory modulators in the brain [37,38] and biological fluids
[39,40] of PD patients. Nevertheless, it has remained unclear whether neuroinflammation is
merely a downstream effect of nerve cell death [41] or if it is primarily involved in PD patho-
genesis. The in vivo data presented here corroborate the hypothesis that DA neuron loss in the
adult brain is strongly facilitated by early onset of neuroinflammation, which supports the
importance of non-cell autonomous mechanisms in the neurodegenerative process. Based on
these findings, we propose that fully differentiated DA neurons can generate a signal that acti-
vates glial cells in response to defective mitochondrial function. The release of a multitude of
immunomodulatory molecules, including pro-inflammatory modulators, likely has a cytotoxic
effect inducing damage to neighboring neurons. Eventually, a self-propelling vicious cycle may
ensue driving a continuously ongoing degeneration of DA neurons. Further studies are
required to define details of the molecular mechanisms linking defective mitochondrial func-
tion to altered immune response. The relevance of these findings for the pathophysiology of
PD needs verification by studies of human tissues.
against IBA1 (green) in panel (D) or GFAP (green) in panel (E) (Scale bars: 100 μm). (F) IBA1 and GFAP immunoreactivities quantified as total
intensity in the stained areas of the midbrain from control and tamoxifen-injected iMfn2DA mice at 3, 6 and 9 weeks after injection. Data are shown as
mean ± SD. n�3.�p< 0.05, ��p<0.01. (G) Log2(FC) of RNA expression of genes involved in signaling pathways that potentially could drive
neuroinflammation in iMfn2DA mice.
https://doi.org/10.1371/journal.pgen.1009822.g005
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Materials and methods
Ethics statement
All animal procedures were conducted in accordance with European, national and institu-
tional guidelines and protocols were approved by the Stockholm ethical committee (Stock-
holms djurförsöksetiska nämnd) under the ethical permit 1206–2019. Animal work also
followed the guidelines of the Federation of European Laboratory Animal Science Associations
(FELASA).
Mouse models
Mice homozygous for a loxP-flanked Mfn2 allele (Mfn2 loxP/loxP) [20] were crossed to hetero-
zygous DATcreERT2 mice [42]. Double heterozygous offspring was obtained and crossed with
Mfn2 loxP/loxP mice to generate iMfn2DA and control mice. The Gt(ROSA26)SorStop–mito–YFP
allele (stop-mitoYFP) [13], that when activated express mitochondrially targeted YFP, was sub-
sequently introduced via additional crossing. At 5–7 weeks of age, iMfn2DA mice were treated
for 5 consecutive days by intraperitoneal injection of 2 mg of tamoxifen (Sigma T5648 dis-
solved in ethanol and sunflower oil) or vehicle. Two different control groups were employed:
the first group (Mfn2 loxP/loxP; DATcreERT2/+) was injected with vehicle and used to assess
motor performance and survival, the second control group (Mfn2 wt/wt; stop-mitoYFP/wt;
DATcreERT2/wt) was injected with tamoxifen and used to visualize mitochondria and isolate
DA neurons from animals with normal mitochondrial function. Analyses of injected controls
and KO mice were performed at 3, 6, and 9 weeks after the last injection. All mice were on the
C57BL/6N background.
Motor performance
The motor activity of vehicle injected control (n>14) and tamoxifen injected iMfn2DA (n>14)
mice was measured by an open field test (VersaMax, AccuScan Instruments) at 3, 6, and 9
weeks after injection. Following an acclimation period of at least 30 min in the ventilated
experimental room, mice were placed individually in activity cages (40 × 40 cm and 30 cm
high) for 60 minutes during the same period (between 4–6 p.m.). A grid of infrared light
beams at floor level and 7.5 cm above recorded spontaneous horizontal and vertical activities
and the total distance travelled was calculated.
In situ hybridization
The expression of Th and Mfn2 transcripts in the DA neurons of the SN was detected as previ-
ously described [20].
Western blot
Ventral midbrain was dissected from control and tamoxifen-injected iMfn2DA mice and snap
frozen in liquid nitrogen. Tissue was homogenized in RIPA buffer supplemented with protease
inhibitors (Complete, Roche). Twenty micrograms of protein extracts were resuspended in
Laemmli buffer, run on 12% SDS–polyacrylamide gel electrophoresis (Invitrogen) and then
transferred onto polyvinylidene difluoride membranes (GE Healthcare). Blots were incubated
overnight at 4˚C with primary antibody against MFN2 (ab 56889, Abcam) and GAPDH
(ab8245, Abcam). Immunodetection was performed according to standard techniques using
enhanced chemiluminescence Immun-Star HRP Luminol/Enhancer (Bio-Rad).
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Immunohistochemistry and confocal microscopy
Mice were perfused with Ca2+/Mg2+ free Tyrode’s solution followed by 4% paraformaldehyde
with 0.4% picric acid in 0.16 M phosphate buffer. The brains were dissected, postfixed for 2
hours, and equilibrated with 10% sucrose. Brains were frozen and cryo-sectioned to obtain 14
(for the striatum) or 20 (for the midbrain) μm thick sections. After 1 hour in blocking solution
(PBS+ 0.3% TrItox X-100+ 1% BSA), the tissue sections were immunolabelled overnight with
primary antibodies against TH (1:500, Pel-Freez; 1:1000, Chemicon), IBA1 (1:1000, Wako),
GFAP (1:1000, Abcam) and CD45 (1:100, Serotec). For fluorescent staining, Cy3- (1:400, Jack-
son Biolabs), Alexa 546- (1:400, Life Technologies) and Alexa 633- conjugated secondary anti-
bodies (1:400, Life Technologies) were used. Confocal images were acquired by sequential
scanning using a LSM800 or LSM880 microscope (Zeiss). Relative intensity of mitoYFP-
labelled mitochondria in the striatum and IBA1, CD45 and GFAP immunoreactivities in the
midbrain were quantified using Fiji software. Confocal images were thresholded and total
intensity was measured using automatic particle counting.
Live microscopy on sorted cells was performed as previously described [43].
Quantification of TH+ neurons and nerve terminals
Vehicle (n = 3) and tamoxifen-injected (n = 3) iMfn2DA mice were perfused at 3, 6 and 9
weeks after injection and the brains were cryo-sectioned. Every sixth midbrain cryo-section
(20 μm thickness) was immunolabelled for TH. For the non-fluorescent labelling, a biotiny-
lated secondary antibody (1:400, Vector Laboratories) was used and the signal was detected by
using a peroxidase substrate (Vector SG, Vector Laboratories). Nuclei of TH-positive neurons
were counted in both right and left hemisphere from 9–11 sections for brain. For the quantifi-
cation of nerve terminals in the striatum, the sections were immunolabelled with antibodies
against TH and fluorescent secondary antibodies. Fiji software was used for the measurement
of TH density.
Quantification of mitochondrial morphology
Mitochondrial morphology analysis of confocal pictures was performed using Fiji software.
TH-positive cells were used to outline the area of interest and apply to the mitochondrial chan-
nel. The mitochondria were measured using a macro containing the Fiji default shape descrip-
tors after applying the same threshold to controls and KO animals. Aspect ratio (AR) of each
mitochondrial object was expressed as the ratio of the major axis/minor axis. The circularity
was calculated as 4π �area/perimeter^2. Results represent a minimum of 12 cells from n = 3
mice per condition (1 = perfectly rounded object; 0 = elongated object).
Dual COX/SDH enzyme histochemistry
Vehicle (n = 3) and tamoxifen-injected (n = 3) iMfn2DA mice were euthanized with carbon
dioxide and decapitated, Brains were rapidly collected and frozen on dry ice. Brain sections
(14 μm) were stained as previously described [44].
Measurements of neurotransmitters
Brains from tamoxifen-injected control and iMfn2DA mice (n� 5 per genotype) were rapidly
dissected, chilled in ice-cold saline and bilateral striatal pieces of the striatum were frozen on
dry ice. Metabolites were extracted from 10–20 mg of mouse tissues in ice cold extraction
buffer (0.37% formic acid in water). After homogenization, the samples were pelleted by cen-
trifugation (21000 x g) for 5 minutes at 4˚C. The obtained supernatant was de-proteinated by
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centrifugation at 4˚C for 10 minutes through a 5 kDa cut-off size exclusion filter (Microcons,
Millipore). The flow-through containing the acidified metabolic extracts (DA, HVA and
5-HT) was immediately separated by HPLC on a reversed phase UPLC column (100 mm x 2.1
mm, C18, Hypersil Gold) held at 25˚C. The eluting metabolites were detected in positive ioni-
zation mode using a ESI MRM (ElectroSpray Ionization Multi Reaction Monitoring) method.
Absolute quantification of the analyzed compounds was obtained by converting the obtained
peak areas from the samples into concentrations derived from the analysis of calibration
curves. Data analysis and peak integration were performed using the TargetLynx software.
Electron microscopy
The mice (n = 3 for each genotype and condition) were perfused with 4% PFA and 0.1% glu-
taraldehyde (Merck) in PBS at 3, 6, and 9 weeks after tamoxifen injection. Brains were dis-
sected and postfixed for 4 hours at 4˚C in the same fixative, washed in PBS, and cut into
100 μm slices with a vibratome (Leica, Germany). Free-floating sections were blocked in 0.1%
Triton X-100 and 10% donkey serum in PBS for 1 hour at room temperature, incubated with
primary rabbit anti-TH antibodies (1:1000, Pel-Freeze) in PBS for 8 hours and secondary don-
key anti-rabbit antibodies conjugated to biotin (1:200, Jackson ImmunoResearch Laborato-
ries) for 4 hours, and stained using Vectastain ABC and DAB kits (Vector Laboratories). The
sections were postfixed in 3% glutaraldehyde and 1% osmium tetroxide, dehydrated in ethanol
and embedded in Durcupan ACM resin (Fluka). In several experiments, sections were stained
with 1% uranyl acetate in 70% ethanol. Serial ultrathin (70 or 100 nm) and semithin (1 μm)
sections were cut with diamond knives (Diatome). Ultrathin sections were collected onto for-
mvar-coated copper grids, counterstained with 1% uranyl acetate and lead citrate and exam-
ined in a Tecnai 12 electron microscope (FEI) equipped with a 2kx2k TemCam-F224HD
camera (TVIPS). Complete series of up to 150 ultrathin sections were used to follow the mor-
phology of cells and synaptic terminals in three dimensions. The mitochondrial aspect ratio
and length were quantified in two TH positive cells for each genotype at 3 weeks after injec-
tion. For each cell, the morphology of 100 mitochondria was analyzed using 3D reconstructed
images from serial ultrathin sections. Quantification of the relative mitochondrial mass (mito-
chondrial area/cytosol) in assessed in TH positive neurons (n>16 cells) for each genotype and
time point.
Isolation of DA neurons by FACS
Brains were dissected from mitoYFP expressing tamoxifen-injected control and iMfn2DA
mice, sectioned and dissociated into single cell suspensions, as previously described [45]. After
dissociation, the mitoYFP positive cells were isolated using a BD FACSAria III Cell Sorter and
collected for mtDNA quantification or RNAseq.
mtDNA measurement
Bulks of 100 mitoYFP positive neurons (n = 4 for genotype and time point) were collected in
lysis buffer (50 mM Tris-HCl pH 8.5, 1 mM EDTA, 0.5% Tween-20, 200 ng/mL Proteinase K).
After centrifugation (7000 g for 10 minutes), DNA extraction was performed at 55˚C for 2
hours followed by 10 minutes at 95˚C to denature Proteinase K. Quantification of mtDNA
copy number was performed using TaqMan Universal Master Mix II and TaqMan probes
against the mitochondrial genes (ND1 and ND6) from Life Technologies. The nuclear 18S
rRNA gene was used as an internal standard.
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Library preparation and sequencing
FACS sorted cells (n�5 per genotype) were used to generate the cDNA libraries according to
the Smartseq2 protocol [23] as previously described [46]. The Nextera XT DNA library prepa-
ration kit (FC-131-1024) was used for cDNA tagmentation. The quality of cDNA and tagmen-
ted cDNA was checked on a High-Sensitivity DNA chip (Agilent Bioanalyzer). Sequencing
was performed on Illumina HiSeq 2500, giving 51 bp reads after de-multiplexing.
Read alignment and gene expression analysis
Reads were aligned to the mouse genome (mm10) merged with eGFP and ERCC spike-in
sequences using Star v2.3.0 [47] and filtered for uniquely mapping reads. Gene expression was
calculated as read counts and as reads per kilobase gene model and million mappable reads
(RPKMs) for each transcript in Ensembl release 75 using rpkmforgenes [48]. Experiments were
performed in technical replicates that were merged. Read counts were summed across techni-
cal replicates and RPKMs were averaged across technical replicates, resulting in gene expres-
sion data for 6 control and 5 iMfn2DA mice. The 23217 protein-coding genes based on the
gene and transcript classification in Ensembl release 75 were selected for further analyses.
For hierarchical clustering, gene counts were first VST-transformed [49], and then the 10%
most varying protein-coding genes (n = 2322) were selected and mean-centered across the 11
biological replicates (6 controls and 5 iMfn2DA mice). Hierarchical clustering was performed
in R using the ward.D2 agglomerative method and the Pearson correlation-based distance
measure. Differential gene expression analysis was performed using DESeq2 [50]. Gene set
enrichment analysis was performed using DAVID Bioinformatics Resources 6.8.
Statistical analysis
All statistical analyses were performed using GraphPad Prism v6 software. All data in the fig-
ures are presented as mean ± SD. Statistical comparisons were performed using single or mul-
tiple Student’s t-test or one-way analysis of variance (ANOVA).
Supporting information
S1 Fig. Loss of Mfn2 in adult DA neurons results in a lethal phenotype. (A) Diagram depict-
ing tamoxifen-induced inactivation of the Mfn2 gene in adult iMfn2DA mice. Mice at 5–7
weeks of age were intraperitoneally injected with tamoxifen for 5 consecutive days and exam-
ined for 3–9 weeks after injection. (B) In situ hybridization showing the expression of Mfn2
and Th transcripts in DA neurons of SN (in the red box). (C) Western blot analysis of MFN2
protein levels in total extracts from ventral midbrain of control and knockout mice at 3 weeks
after tamoxifen injection. GAPDH was used as a loading control. (D) Survival of iMfn2DA and
control mice after tamoxifen injection. iMfn2DA mice had a median survival of 11,6 weeks.
���p< 0.001 n = 15. (E) Body weight of control and iMfn2DA mice (males and females) after
tamoxifen or vehicle injection. ��p< 0.01 n>10. (F) Analysis of 5-HT levels in the striatum at
3, 6, and 9 weeks after tamoxifen injection. n�5. Data are shown as mean ± SD.
(TIF)
S2 Fig. Mitochondrial morphology in tamoxifen-injected iMfn2DA mice. (A) Visualization
of mitochondria in DA neurons in vivo. The expression of mitoYFP (green) overlaps with TH
(red) labelling of midbrain DA neurons (Scale bars: 50 μm). (B) Representative confocal
microscopy images of mitoYFP-labelled mitochondria (green) in TH immunoreactive neu-
rons (red) at 2 weeks after tamoxifen injection (Scale bar: 10 μm). (C) Representative transmis-
sion electron microscopy images of DA neurons. The lines mark the nuclear (N) and the
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plasma membrane (Scale bars: 5 μm). (D) Quantification of aspect ratio and mitochondrial
length at 3 weeks after injection in two cells for each genotype using serial ultrathin sections.
���p< 0.001. (E) Quantification of the relative mitochondrial mass (mitochondrial area/cyto-
sol) in TH+ DA neurons from EM images at 3, 6 and 9 weeks after injection. ���p< 0.001,
n>16 cells for each genotype. (F) EM images of mitochondria from perinuclear region of DA
neurons with disrupted OMM 6 and 9 weeks after tamoxifen injection (Scale bar: 1μm). (G)
Electron micrographs of DA nerve terminals, delineated by the light blue lines, in striatum 6
and 9 weeks after tamoxifen injection (Scale bars: 500 nm).
(TIF)
S3 Fig. Immune response in tamoxifen-injected iMfn2DA mice. (A) Representative confocal
microscopy images of mitoYFP+ cells obtained with the DA neuron isolation protocol from
control mice injected with tamoxifen (Scale bar: 5 μm and 20 μm). (B) Representative confocal
microscopy images of control and iMfn2DA mouse midbrain 3, 6, and 9 weeks after tamoxifen
injection. The brain sections were stained with antibodies against CD45 (red) and TH (blue)
(Scale bars: 50 μm). (C) CD45 immunoreactivity quantified as total intensity in the stained
areas of the midbrain from control and tamoxifen-injected iMfn2DA mice at 3, 6 and 9 weeks
after injection. Data are shown as mean ± SD. n�3.�p< 0.05. (D) RNA expression levels
(RPKM) of the markers of activated microglial cells Aif1 (Iba1), Tmem119, Ptprc (Cd45) and
Itgam (Cd11b) in mitoYFP+ samples isolated from iMfn2DA and control mice. (E) Cell-type
markers in isolated mitoYFP+ and mitoYFP- cells. Heatmaps showing RNA levels (RPKM) of
genes encoding: ii) microglial and ii) astrocyte markers, which are more abundant in
mitoYFP- samples. Data are shown as mean of the RPKM in control (n = 6), iMfn2DA (n = 5),
and mitoYFP- (n = 3) mice.
(TIF)
S1 Table. List of the 439 genes found differentially expressed in iMfn2DA mice at adjusted
p value (padj) of <0.05.
(XLSX)
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